Figure 4. Proportion of Novel Therapeutics Approved by the US Food and Drug Administration (FDA) Between 2001 and 2010 Affected by Any Postmarket Safety Event, According to Accelerated Approval, Orphan Status, Near–Regulatory Deadline Approval, and Regulatory Review Time.